Kelvin Teo, MBBS, PhD, senior consultant, Advanced Eye Clinic & Surgery, adjunct associate professor, Duke NUS Eye ACP, Singapore, presents real-world data showing that a single 8-mg dose…
Andrew Chang, MBBS, PhD, consultant ophthalmologist and head of Ophthalmology, Sydney Eye Hospital, Australia, shares real-world experience using 8-mg intravitreal aflibercept for neovascular age-related macular degeneration and reports…
The proportion of risk for alcohol use disorder (AUD) that can be attributed to genetic factors is as high as 60%. This data invokes heritability comparisons to both…
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center in Boston, Massachusetts presented results from the KEYNOTE-427 study at the Genitourinary Cancers…
The Centers for Disease Control and Prevention (CDC) has produced a new video for healthcare providers who treat or dispense medications to women of reproductive age. This short…
A phase 1b study showed pembrolizumab and axitinib extended both overall survival (OS) and progression-free survival (PFS) in patients with previously untreated mRCC. “The risk of death was…
Historically, high-sensitivity diagnostic testing for many common diseases consisted of sending samples to an offsite laboratory and potentially waiting hours or days before results were attained and shared…
Abbott has developed two types of implantable neurostimulation devices that employ two advanced spinal column stimulation (SCS) techniques, respectively, dorsal root ganglion (DRG) stimulation and Abbott’s proprietary BURSTDR™…
Exoskeletons intended for medical purposes are motorized braces that help control a patient’s body and limb movements. These sophisticated body frames are increasingly being used as a tool…
Deep brain stimulation (DBS) is a widely-used neurological technique for modifying and rehabilitating brain function. Closed-loop or “smart” DBS systems currently under development are the next evolutionary step…
Alcohol use disorder (AUD) is notoriously difficult to treat, but a new therapeutic option may be on the horizon. Ondansetron, a competitive serotonin type 3 receptor antagonist currently…
